Business Description
MediPharm Labs Corp
NAICS : 325410
SIC : 3741
ISIN : CA69354Q1090
Total Employee Number:
127Compare
Compare
Traded in other countries / regions
LABS.CanadaMEDIF.USAMLZ.Germany IPO Date
2018-02-09Description
MediPharm Labs Corp and its subsidiaries produce cannabis, purified and pharmaceutical-like cannabis extracts, related derivative products, and cannabis-related medical information and services. Its operating subsidiaries hold cultivation, standard processing, and sale licences under the Cannabis Act (Canada), allowing the cultivation, sale, and distribution of cannabis oil, extracts, edibles, topicals, dried and fresh cannabis, and derivatives to authorized purchasers. Its subsidiary provides clinic services to Canadian patients requiring medical cannabis education and prescriptions. The company operates in one reportable segment, the production and sales of cannabis flower, and generates maximum revenue from Canada, with additional international sales.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 548.11 | |||||
Equity-to-Asset | 0.81 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -2.41 | |||||
Beneish M-Score | -3.35 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.5 | |||||
3-Year EBITDA Growth Rate | 45.3 | |||||
3-Year EPS without NRI Growth Rate | 42.3 | |||||
3-Year FCF Growth Rate | 40.3 | |||||
3-Year Book Growth Rate | -24.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 78.2 | |||||
9-Day RSI | 64.03 | |||||
14-Day RSI | 56.42 | |||||
3-1 Month Momentum % | 15.38 | |||||
6-1 Month Momentum % | 7.14 | |||||
12-1 Month Momentum % | 15.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.02 | |||||
Quick Ratio | 2.03 | |||||
Cash Ratio | 1.16 | |||||
Days Inventory | 107.75 | |||||
Days Sales Outstanding | 56.69 | |||||
Days Payable | 56.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.6 | |||||
Shareholder Yield % | 2.19 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 30.29 | |||||
Operating Margin % | -20.52 | |||||
Net Margin % | -20.21 | |||||
EBITDA Margin % | -16.33 | |||||
FCF Margin % | -7.8 | |||||
OCF Margin % | -7.66 | |||||
ROE % | -22.8 | |||||
ROA % | -18.43 | |||||
ROIC % | -29.54 | |||||
3-Year ROIIC % | -249.42 | |||||
ROC (Joel Greenblatt) % | -32.33 | |||||
ROCE % | -22.63 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.74 | |||||
PB Ratio | 0.9 | |||||
Price-to-Tangible-Book | 0.94 | |||||
EV-to-EBIT | -2.54 | |||||
EV-to-EBITDA | -3.12 | |||||
EV-to-Forward-EBITDA | 17.91 | |||||
EV-to-Revenue | 0.51 | |||||
EV-to-Forward-Revenue | 0.65 | |||||
EV-to-FCF | -6.52 | |||||
Price-to-GF-Value | 1.07 | |||||
| Price-to-Net-Current-Asset-Value | 1.88 | |||||
Earnings Yield (Greenblatt) % | -39.37 | |||||
FCF Yield % | -10.59 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MediPharm Labs Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 43.281 | ||
| EPS (TTM) (C$) | -0.02 | ||
| Beta | -0.5282 | ||
| 3-Year Sharpe Ratio | 0.32 | ||
| 3-Year Sortino Ratio | 0.56 | ||
| Volatility % | 41.96 | ||
| 14-Day RSI | 56.42 | ||
| 14-Day ATR (C$) | 0.004785 | ||
| 20-Day SMA (C$) | 0.07075 | ||
| 12-1 Month Momentum % | 15.38 | ||
| 52-Week Range (C$) | 0.06 - 0.1 | ||
| Shares Outstanding (Mil) | 424.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MediPharm Labs Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MediPharm Labs Corp Stock Events
| Event | Date | Price (C$) | ||
|---|---|---|---|---|
| 0.5:1 Stock Split | 2018-10-04 | 1.00 (+0.00%) |
Show
Entries
MediPharm Labs Corp Frequently Asked Questions
What is MediPharm Labs Corp(TSX:LABS)'s stock price today?
The current price of TSX:LABS is C$0.08. The 52 week high of TSX:LABS is C$0.10 and 52 week low is C$0.06.
When is next earnings date of MediPharm Labs Corp(TSX:LABS)?
The next earnings date of MediPharm Labs Corp(TSX:LABS) is .
Does MediPharm Labs Corp(TSX:LABS) pay dividends? If so, how much?
MediPharm Labs Corp(TSX:LABS) does not pay dividend.
Press Release
Articles on MediPharm Labs Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers